Pilgrim Global buys Sable Offshore (SOC) shares worth $14.7m
HALIFAX - Appili Therapeutics Inc. (TSX:APLI; OTCPink:APLIF), a microcap biopharmaceutical company with a market capitalization of $1.32 million, announced Tuesday that shareholders approved all proposed resolutions during the company’s annual and special meeting. According to InvestingPro data, while the company isn’t currently profitable, analysts expect net income growth this year.
Shareholders elected six directors to the board: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd. Each director received over 99% approval from voting shareholders.
The biopharmaceutical company, which focuses on infectious disease and biodefense drug development, also secured shareholder approval to reappoint PricewaterhouseCoopers, LLP as independent auditor for the coming year.
Additional approved resolutions included unallocated options under the company’s rolling 10% stock option plan and unallocated awards under its equity incentive plan.
Matkovits, Froehlich, and Gowd each received 99.84% approval from shareholders, while Cilla and Balboni secured 99.39% support. Bloom received 99.41% of votes cast.
Appili Therapeutics is currently developing several anti-infective treatments, including an FDA-approved metronidazole suspension for antimicrobial resistant infections, a tularemia vaccine candidate, and a topical treatment for cutaneous leishmaniasis.
The company has filed detailed voting results on its SEDAR+ profile, according to the press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.